rss
Br J Ophthalmol 2009;93:782-786 doi:10.1136/bjo.2008.144535
  • Clinical science
    • Original Article

A randomised crossover study comparing bimatoprost and latanoprost in subjects with primary angle closure glaucoma

  1. A C S How1,
  2. R S Kumar2,
  3. Y-M Chen3,
  4. D H Su1,
  5. H Gao3,
  6. F T Oen1,
  7. C-L Ho1,
  8. S K Seah1,
  9. T Aung1,2,4
  1. 1
    Singapore National Eye Centre, Singapore
  2. 2
    Singapore Eye Research Institute, Singapore
  3. 3
    Clinical Trials and Epidemiology Research Unit, Singapore
  4. 4
    Yong Loo Lin School of Medicine, National University of Singapore, Singapore
  1. Dr T Aung, Singapore National Eye Centre, 11 Third Hospital Avenue, Singapore 168751; tin11{at}pacific.net.sg
  • Accepted 20 December 2008
  • Published Online First 30 March 2009

Abstract

Background/aims: To compare the intraocular pressure (IOP) lowering efficacy and side effects of latanoprost 0.005% and bimatoprost 0.03% in subjects with chronic primary angle closure glaucoma (PACG).

Methods: This was an observer-masked randomised crossover study of 60 PACG subjects who received either latanoprost or bimatoprost for 6 weeks, after which they were crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications was assessed by the reduction in IOP after 6 weeks of treatment compared with baseline.

Results: Fifty-four subjects (80 eyes) completed the study. Latanoprost reduced IOP (mean (SD)) by 8.4 (3.8) mm Hg and bimatoprost by 8.9 (3.9) mm Hg from a baseline of 25.2 (3.6) mm Hg and 25.2 (3.6) mm Hg respectively (p = 0.23). Adverse events were mild in both groups; however there were twice as many reports of an adverse event in the bimatoprost group (81%) compared with the latanoprost group (40%, p<0.01). Ocular irritation was the most frequently reported adverse event in both groups; 22 subjects (37.9%) treated with bimatoprost experienced ocular hyperaemia as compared with 13 subjects (22.4%) treated with latanoprost (p = 0.11).

Conclusions: Bimatoprost once daily was similarly effective in reducing IOP compared with latanoprost once daily in subjects with chronic PACG. Both drugs were well tolerated with mild ocular adverse events.

Footnotes

  • Competing interests: TA has received research funding, travel support and honoraria from Allergan and has been a consultant and received travel support and honoraria from Pfizer.

  • Funding: This research was funded by an unrestricted grant from Allergan.

  • Ethics approval: Ethics approval was provided by the Ethics Committee of the Singapore Eye Research Institute.

  • Patient consent: Obtained.

Relevant Article

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All versions of this article:
    1. bjo.2008.144535v1
    2. 93/6/782 most recent

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.